Premier Alternatives

Primmune Therapeutics

San Diego, CA · Founded 2017 · Privately Held (backing)

Developer of an orally administered toll-like receptor agonist designed to stimulate innate immunity in cancer immunotherapy. Primmune Therapeutics is based in San Diego, CA and was founded in 2017. It was valued at $44 million at its early-stage round in Jan 2021, the last priced event on record. It has raised $63.2 million across 5 recorded rounds; the latest was a $13 million early-stage round in Oct 2020.

PMV mark · valuation
$44.0M
Oct 2026
Priced at
its early-stage round
Jan 2021
Total raised
$63.2M
Last round
Early Stage VC
Oct 2020

Primmune Therapeutics key facts

as of Oct 2026
  • Developer of an orally administered toll-like receptor agonist designed to stimulate innate immunity in cancer immunotherapy.
  • Primmune Therapeutics is valued at approximately $44.0M as of Oct 2026, set at its early-stage round, Jan 2021; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $63.2M across 5 recorded rounds; the latest was Early Stage VC ($13.0M) in Oct 2020.
  • Notable investors include Johnson & Johnson Innovation - JLABS, Polaris Partners, Samsara BioCapital, CAM Capital, BioRock Ventures — 9 tracked in total.
  • Primmune Therapeutics has filed 6 Form Ds with the SEC since 2017, most recently Nov 2020 ($13.0M sold to 12 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$44.0M

Valued at $44.0M at its early-stage round, Jan 2021. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Primmune Therapeutics with a free account
  • ·Watch Primmune Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Primmune Therapeutics funding rounds

5 rounds
Oct 2020Early Stage VC$13.0MSEC filing▮
Feb 2020Seed Round$2.5MSEC filing▮
Feb 2019Seed Round$2.0MSEC filing▮
Jul 2018Seed Round$1.1MSEC filing▮
Oct 2017Seed Round$1.5MSEC filing▮
Full funding history →

Primmune Therapeutics valuation

Primmune Therapeutics was valued at $44 million at its early-stage round in Jan 2021. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Primmune Therapeutics raised?

Primmune Therapeutics has raised $63.2 million in total; 5 of its rounds are on record, from 2017 on. The largest on record was a $2.5 million seed round in Feb 2020; the most recent was a $13 million early-stage round in Oct 2020.

Primmune Therapeutics has filed 6 Form Ds with the SEC since 2017, most recently in Nov 2020 ($13 million sold to 12 investors).

Primmune Therapeutics investors

9 investors are on record for Primmune Therapeutics, including Johnson & Johnson Innovation - JLABS, Polaris Partners, Samsara BioCapital and CAM Capital. The early-stage round in Oct 2020 drew 12 investors.

About Primmune Therapeutics

Developer of an orally administered toll-like receptor agonist designed to stimulate innate immunity in cancer immunotherapy. The company's agonist produces cytokines and chemokines that up-regulate general cellular response and facilitate natural killer cell activation, enabling medical practitioners to address all metastatic diseases and stimulate B-cell proliferation and activation.

Sector
Healthcare
HQ
San Diego, CA, United States
Founded
2017
Employees
10
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.